A Selection of Recent Papers

Meta-data Analysis as a Strategy to Evaluate Individual and Common Features of Proteome Changes in Breast Cancer. O. ZAKHARCHENKO, C. GREENWOOD, A. LEWANDOWSKA, U. HELLMAN, L. ALLDRIDGE, S. SOUCHELNYTSKYI (Stockholm; Uppsala, Sweden; Chelmsford, UK; Olsztyn, Poland; Gold Coast, QLD, Australia)

Circadian Transcription Profile of Mouse Breast Cancer under LD and DD Conditions. E.-Y. OH, X. YANG, A. FRIEDMAN, C.M. ANSELL, J. DUQUITON, D.F. QUITON, P.A. WOOD, W.J.M. HRUSHESKY (Columbia, SC; St. Louis, MO, USA)

Interleukin 6/Interleukin 6 Receptor Interaction and its Role as a Therapeutic Target for Treatment of Cachexia and Cancer. U.H. WEIDLE, S. KLOSTERMANN, D. EGGLE, A. KRÜGER (Munich, Germany)

A Biotin Label-based Antibody Array for High-content Profiling of Protein Expression. R. HUANG, W. JIANG, J. YANG, Y.Q. MAO, Y. ZHANG, W. YANG, D. YANG, B. BURKHOLDER, R.F. HUANG, R.-P. HUANG (Norcross, GA, USA; Guangzhou, P.R. China)

TGF-β1 Interactome: Metastasis and Beyond. M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAL, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (Düsseldorf, Germany)

Molecular Profiling Using Tissue Micrarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLGERSON, S. EKMAN, J. REIZENSTEIN, R.F. HUANG, H. SCHMETZER (Düsseldorf, Germany)

Proteomic Study of Sera from Patients with Bladder Cancer: Usefulness of S100A8 and S100A9 Proteins. S. MINAMI, Y. SATO, T. MATSUMOTO, K. YOSHIO, J.-I. ISHII, K. MATSUMOTO, R. NAGASHIO, I. OKAYASU (Kanagawa, Japan)

Analysis of Protein Phosphorylation in Cisplatin-treated Human Cells Following Annexin V-based Separation and Multi-Antibody Screening. E. O’MEARA, S. CRUET-HENNEQUART, M.P. CARTY (Galway, Ireland)


DNA-based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (Pomona, CA, USA)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J.A. ALRUWAILI, S.T. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, C.L. AUKIM-HASTIE, P.A. TOWNSEND (Hampshire, UK; Riyadh, Kingdom of Saudi Arabia; Boston, MA, USA)

Effects of Artesunate on Cytokinesis and G2/M Cell Cycle Progression of Tumour Cells and Budding Yeast. L. STEINBRÜCK, G. PEREIRA, T. EFFERTH (Heidelberg; Mainz, Germany)

Use of NG2 (7.1) in AML as a Tumor Marker and its Association with a Poor Prognosis. K. PETROVICI, M. GRAF, K. HECHT, S. REIF, K. PFISTER, H. SCHMETZER (Regensburg; Munich, Germany)
Instructions to Authors

General Policy. ANTIcancer RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant their contribution(s) in the appropriate section(s) of the presented work; (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

**Submission of Manuscripts.** Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)

2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.

3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

   John G. Delinassios  
   International Institute of Anticancer Research (IIAR)  
   Editorial Office of ANTICANCER RESEARCH,  
   IN VIVO, CANCER GENOMICS and PROTEOMICS.  
   1st km Kapandritiou-Kalamou Road  
   P.O. Box 22, GR-19014 Kapandriti, Attiki  
   GREECE

Submitted articles will not be returned to Authors upon rejection.

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

**Reprints.** Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Expression of Zinc Finger 23 Gene in Human Hepatocellular Carcinoma. Y. SHI, L. ZHENG, G. LUO, J. WEI, J. ZHANG, Y. YU, Y. FENG, M. LI, N. XU (Changzhou, PR China; Lund, Sweden) .............................. 3595


Identification of The Distinctive Type i/Xho I+ Strain of Epstein-Barr Virus in Gastric Carcinoma in Peru. P. ORDONEZ, C. KORIYAMA, S. DING, E. YOSHIIWARA, A.H. CORVALAN, J. TAKANO, J.L. CHIRINOS, J. WATANABE, J. MIYAGUI, H. HIDALGO, P. CHACON, V. LINARES, Y. EIZURU, S. AKIBA (Kagoshima, Japan; Lima; Huanuco; Chiclayo, Peru; Santiago, Chile) ........................................................... 3607

Lower Serum Total Testosterone is Associated with Lymph Node Metastases in a Radical Prostatectomy Cohort Study. C. KRATZIK, I. WOMASTEK, C. BIEGLMAYER, G. SCHATZL, J. LACKNER, C. FREIBAUER, G. LUNGLMAYR (Wien; Mistelbach, Austria) .............................................................. 3615

Vitamin D in Colorectal, Breast, Prostate and Lung Cancer: A Pilot Study. P. PAZDIORA, S. SVOBODOVA, R. FUCHSOVA, R. KUCERA, M. PRAZAKOVA, J. VRZALOVA, A. NARANSKA, M. STRAKOVA, I. TRESKOVA, L. PECEN, V. TRESKA, L. HOLUBE FJR., M. PESEK, J. FINEK, O. TOPOLCAN (Pilsen; Prague, Czech Republic) ....................................................... 3619

Effect of Ibandronate on Disseminated Tumor Cells in the Bone Marrow of Patients with Primary Breast Cancer: A Pilot Study. O. HOFFMANN, B. AKTAS, C. GOLDAU, M. HEUBNER, C. OBERHOF, R. KIMMIG, S. KASIMIR-BAUER (Essen, Germany) .......................................................................................................................... 3623


An Evaluation of Prognostic Value of Death-associated Protein Kinase 1 in Breast Cancer. S.-E. CHOU, C.-Y. HUANG, S.-M. SHEEN-CHEN, Y.-W. LIU, C.-H. TSAI, Y.-H. LIN, C.-C. HUANG, R.-P. TANG (Kaohsiung; Linkou, Taiwan, ROC; Xiamen, PR China) ..................................................................................... 3633

Errata ........................................................................................................................................ 3637

Book Reviews .................................................................................................................................... 3639

Announcements ................................................................................................................................ 3643

* Reviews (pages 3489, 3503, 3543)
Oxaliplatin Scale and National Cancer Institute-Common Toxicity Criteria in the Assessment of Chemotherapy-induced Peripheral Neuropathy. A.-L. KAUTIO, M. HAANPÄÄ, H. KAUTIAINEN, A. LEMINEN, E. KALSO, T. SAARTO (Helsinki; Jyväskylä; Tampere, Finland) ................................................................. 3493

Bowel Complication during Robotic-assisted Laparoscopic Radical Prostatectomy. C.-F. HUNG, C.-K. YANG, C.-L. CHENG, Y.-C. OU (Taichung, Taiwan, ROC) .................................................................................... 3497

* Review: The Prognostic Role of Lymphovascular Invasion in Urothelial-cell Carcinoma of Upper and Lower Urinary Tract. E. BRUNOCILLA, R. PERNETTI, G. MARTORANA (Bologna, Italy) .................. 3503

Sunitinib Re-challenge in Metastatic Renal Cell Carcinoma Treated Sequentially with Tyrosine Kinase Inhibitors and Everolimus. B. PAULE, N. BRION (Creteil; Guyancourt, France) ................................. 3507


Expression of Thymidylate Synthase and Dihydropyrimidine Dehydrogenase in Primary Oral Squamous Cell Carcinoma and Corresponding Metastases in Cervical Lymph Nodes: Association with the Metastasis Suppressor CD82. G. KAWASAKI, I. YOSHITOMI, S. YANAMOTO, S.-I. YAMADA, A. MIZUNO, M. UMEDA (Nagasaki, Japan) .............................................................. 3521

Severe Late Complications in Patients with Uterine Cancer Treated with Postoperative Radiotherapy. G. KASUYA, K. OGAWA, S. IRAHA, Y. NAGAI, M. SHIRAISHI, M. HIRAKAWA, H. SAMURA, T. TOITA, Y. KAKINOHANA, W. KUDAKA, M. INAMINE, T. ARIGA, T. NISHIMAKI, Y. AOKI, S. MURAYAMA (Okinawa, Japan) .......................................................... 3527


* Review: The Role of Chemotherapy in Metastatic Gastric Cancer. F. PASINI, A.P. FRACCON, G. DE MANZONI (Rovigo; Verona, Italy) .................................................................................. 3543

Hypofractionated Radiotherapy with or without IGRT in Prostate Cancer: Preliminary Report of Acute Toxicity. M. VALERIANI, F. MONACO, M.F. OSTI, V. DE SANCTIS, G. MINNITI, R.M. ENRICI (Rome, Italy) .... 3555


Efficacy of Meloxicam in Combination with Preoperative Chemotherapy for Breast Cancer - Japan Breast Cancer Research Network (JBCRN) 02-1 Trial. D. YAMAMOTO, S. IWASE, H. YOSHIDA, Y. KURODA, C. YAMAMOTO, K. KITAMURA, H. ODAGIRI, Y. NAGUMO (Osaka; Tokyo; Fukuoka; Hirosaki, Japan) ...... 3567

Metabolic Activation of Irinotecan during Intra-arterial Chemotherapy of Metastatic Colorectal Cancer. M. CZEJKA, A. KISS, C. KOESSNER, R. TERSKOL, D. ETTLINGER, J. SCHEUSSLER (Vienna, Austria) ................................. 3573


Contents continued on the preceding page


**Clinical Studies**


Case Report of Pneumatosis Intestinalis Secondary to Sunitinib Treatment for Refractory Gastrointestinal Stromal Tumor. A. JARKOWSKI III, R. HARE, V. FRANCESCUITI, N. WILKINSON, N. KHUSHALANI (Buffalo, NY, USA) ................................................................. 3429

Diagnostic Value of 16 Cellular Tumor Markers for Metastatic Thyroid Cancer: An Immunohistochemical Study. H. LIANG, Y. ZHONG, Z. Luo, Y. HUANG, H. LIN, S. ZHAN, K. XIE, Q.Q. LI (Beihai; Nanning; Pingnan; Guangzhou, China; Bethesda, MD, USA) ................................................................. 3433

Conventional Cytogenetics and Breakpoint Distribution by Fluorescent In Situ Hybridization in Patients with Malignant Hemopathies Associated with inv(3)(q21;q26) and t(3;3)(q21;q26). E. DE BRAEKELEER, N. DOUET-GUILBERT, A. BASINKO, C. BOVO, N. GUÉGANIC, M.-J. LE BRIS, F. MOREL, M. DE BRAEKELEER (Brest, France) ................................................................. 3441

Phase II Study of Topotecan with Cisplatin in Japanese Patients with Small Cell Lung Cancer. Y. HOSOMI, M. SHIBUYA, S. NIHO, Y. CHINOSE, K. KIURA, H. SAKAI, K. TAKEDA, S. KUDO, K. EGUCHI, K. MATSUI, Y. MASUDA, M. ANDO, K. WATANABE (Tokyo; Chiba; Fukuoka; Okayama; Saitama; Osaka; Kanagawa; Fukushima, Japan) ................................................................. 3449


Clinicopathological Study of Poorly Differentiated Colorectal Adenocarcinomas: Comparison between Solid-type and Non-solid-type Adenocarcinomas. K. KOMORI, Y. KANEMITSU, S. ISHIGURO, Y. SHIMIZU, T. SANO, S. ITO, T. ABE, K. MISAWA, Y. ITO, N. UEMURA, T. KATO (Nagoya, Aichi, Japan) ................................................................. 3463


Patterns of Failures in Endometrial Cancer: Clinicopathological Variables Predictive of the Risk of Local, Distant and Retroperitoneal Failure. A. GADDucci, S. COSIO, M.G. FABRINI, A. FANUCCHI, C. BARSOTTI, R. CRISTOFANI, C. GRECO, A.R. GENAZZANI (Pisa, Italy) ................................................................. 3483

Polo-like Kinase 1 Inhibition as a New Therapeutic Modality in Therapy of Cholangiocarcinoma. S. THRUM, J. LORENZ, J. MÖSSNER, M. WIEDMANN (Leipzig; Berlin, Germany) .................................................. 3289


Biodistribution of $^{131}$I-labeled Anti-CK8 Monoclonal Antibody in HNSCC in Xenotransplanted SCID Mice. M. ANDRATSCHKE, C.W. LUEBBERS, V. JOHANNSON, B. SCHMITT, B. MACK, R. ZEIDLER, S. LANG, B. WOLLENBERG, F.J. GILDEHAUS (Munich; Luebeck; Essen, Germany) ........................................ 3315

Combination of Resveratrol and Antiandrogen Flutamide Has Synergistic Effect on Androgen Receptor Inhibition in Prostate Cancer Cells. L. KAI, A.S. LEVENSON (Jackson, MS, USA) .................................................. 3323

Up-regulation of 42 kDa Tubulin Alpha-6 Chain Fragment in Well-differentiated Hepatocellular Carcinoma Tissues from Patients Infected with Hepatitis C Virus. Y. KURAMITSU, M. TAKASHIMA, Y. YOKOYAMA, N. IIZUKA, T. TAMESA, J.K. AKADA, Y. WANG, T. TODA, I. SAKAIDA, K. OKITA, M. OKA, K. NAKAMURA (Ube; Tokyo, Japan) .................................................. 3331

Effects of Non-motorized Voluntary Running on Experimental and Spontaneous Metastasis in Mice. L. YAN, L.C. DEMARS (Grand Forks, ND, USA) .......................................................... 3337


Antitumor Effect of New HER2 Peptide Vaccination Based on B Cell Epitope. H. MIYAKO, Y. KAMETANI, I. KATANO, R. ITO, B. TSUDA, A. FURUKAWA, Y. SAIITO, D. ISHIKAWA, K. OGINO, S. SASAKI, K. IMAI, S. HABU, H. MAKUUCHI, Y. TOKUDA (Kanagawa; Saitama; Tokushima; Hokkaido; Tokyo, Japan) .......................... 3361

Effects of Acute and Chronic Hypoxia on the Radiosensitivity of Gastric and Esophageal Cancer Cells. Y. KATO, M. YASHIRO, Y. FUYUHIRO, S. KASHIWAGI, J. MATSUOKA, T. HIRAKAWA, S. NODA, N. AOMATSU, T. HASEGAWA, T. MATSUZAKI, T. SAWADA, M. OHIRA, K. HIRAKAWA (Osaka, Japan) .................................................. 3369

Down-regulation of EGFL8: A Novel Biomarker for Advanced Gastric Cancer. F. WU, A. SHIRAHATA, K. SAKURABA, Y. KITAMURA, T. GOTO, M. SAIITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (Guangzhou, China; Yokohama, Japan) .................................................. 3377

Increased Soluble Leptin Receptor Levels Are Associated with Advanced Tumor Stage in Colorectal Cancer Patients. V. TUTINO, M. NOTARNICOLA, V. GUERRA, D. LORUSSO, M.G. CARUSO (Castellana Grotte, Bari, Italy) .................................................. 3381


Thiamine Supplementation Attenuated Hepatocellular Carcinoma in the Atp7b Mouse Model of Wilson’s Disease. C.T. SHELINE (New Orleans, LA, USA) .................................................. 3395

Effects of Cytokinins, Cytokinin Ribosides and their Analogs on the Viability of Normal and Neoplastic Human Cells. S. CASATI, R. OTTRIA, E. BALDOLI, E. LOPEZ, J.A.M. MAIER, P. CIUFFREDA (Milan, Italy) .... 3401

Contents continued on the preceding page
TGF-β Regulation of Focal Adhesion Proteins and Motility of Premalignant Oral Lesions via Protein Phosphatase 1. J.E. WALSH, M.R. YOUNG (Charleston, SC, USA) ................................................................. 3159

Anticancer Activity of Branched-chain Derivatives of Oleic Acid. O.D. DAILEY JR., X. WANG, F. CHEN, G. HUANG (New Orleans, LA; Clemson, SC, USA) ............................................................... 3165

Enhanced Efficacy of Gemcitabine by Indole-3-carbinol in Pancreatic Cell Lines: The Role of Human Equilibrative Nucleoside Transporter 1. H. WANG, B.R. WORD, B.D. LYN-COOK (Jefferson, AR, USA) .... 3171

Silencing of Selected Glutamate Receptor Subunits Modulates Cancer Growth. H. LUJKSH, O. UCKERMANN, A. STEPULAK, S. HENDRUSCHK, J. MARZAHN, S. BASTIAN, C. STAUFNER, A. TEMME, C. IKONOMIDOU (Dresden; Heidelberg, Germany; Lublin, Poland; Madison, WI, USA) .............. 3181

Paclitaxel and TRAIL Synergize to Kill Paclitaxel-resistant Small Cell Lung Cancer Cells through a Caspase-independent Mechanism Mediated through AIF. T.B. HUNTER, N.J. MANIMALA, K.A. LUDDY, T. CATLIN, S.J. ANTONIA (Tampa, FL, USA) ................................................................. 3193

Metastasis Suppressor-1, MTSS1, Acts as a Putative Tumour Suppressor in Human Bladder Cancer. P. DU, L. YE, F. RUGE, Y. YANG, W.G. JIANG (Cardiff, UK; Beijing, PR China) ............................................................... 3205

Cytotoxicity of Chalcone Derivatives towards Glioblastoma. P. CHAMPELOVIER, M. MININNO, E. DUCHAMP, E. NICOLLE, V. CURRI, A. BOUMENDJEL, J. BOUTONNAT (Grenoble, France) ................... 3213


Intracellular Metabolism, Subcellular Localization and Phototoxicity of HMME/HB in Ovarian Cancer Cells. K. SONG, J. LI, L. LI, P. ZHANG, F. GENG, R. DONG, Q. YANG, X. QU, B. KONG (Jinan, Shandong, PR China) ............................................................................................................. 3229

The Role of the 3D Environment in Hypoxia-induced Drug and Apoptosis Resistance. J.W. KIM, W.J. HO, B.M. WU (Los Angeles, CA, USA) ........................................................................................................ 3237

Anticancer SAR Models for MCF-7 and MDA-MB-231 Breast Cell Lines. S. QAMAR, C.A. CARRASQUER, S.L. CUNNINGHAM, A.R. CUNNINGHAM (Louisville, KY, USA) ......................................................... 3247

Down-regulation of EGFR Prolonged Cell Growth of Glioma but Did Not Increase the Sensitivity to Temozolomide. N. INABA, K. FUJIOKA, H. SAITO, M. KIMURA, K. IKEDA, Y. INOUE, S. ISHIZAWA, Y. MANOME (Tokyo, Japan).............................................................................. 3253

Fluvastatin Enhances Sorafenib Cytotoxicity in Melanoma Cells via Modulation of AKT and JNK Signaling Pathways. S. ZHANG, N.A. DOUDICAN, E. QUAY, S.J. ORLOW (New York, NY, USA) .............................................................................. 3259

Epigenetic Modifiers Exert Renal Toxicity through Induction of p66shc. I. ARANY, J.S. CLARK, I. EMBER, L.A. JUNCOS (Jackson, MS, USA; Pecs, Hungary) ................................................................. 3267

Oncostatin M and IL-6 Induce u-PA and VEGF in Prostate Cancer Cells and Correlate In Vivo. T. W. WEISS, R. SIMAK, C. KAUN, G. REGA, H. PFLUGER, G. MAURER, K. HUBER, J. WOJTA (Vienna, Austria; Ulleval, Norway) ........................................................................................................ 3273

Prevention of Mouse Lung Tumors by Combinations of Chemopreventive Agents Using Concurrent and Sequential Administration. B.C. CASTO, M.A. PEREIRA (Columbus, OH, USA) .............................................................................. 3279

Modulation of Multidrug Efflux Pump Activity by New Hydantoin Derivatives on Colon Adenocarcinoma Cells without Inducing Apoptosis. G. SPENGLER, J. HANZLIK, I. OCOSVOSZKI, M. VIVEIROS, K. KIEC-KONONOWICZ, J. MOLNAR, L. AMARAL (Szeged, Hungary; Lisboa, Portugal; Cracow, Poland; Brussels, Belgium) ........................................................................................................ 3285

Contents continued on the preceding page